Amifostine, Carboplatin, and Paclitaxel

The combination of amifostine, carboplatin, and paclitaxel is a therapeutic regimen that has been studied in various cancer types, particularly in advanced endometrial cancer, non-small cell lung cancer (NSCLC), and squamous cell carcinoma of the head and neck (SCCHN). ### Composition and Mechanism This is a combination therapy consisting of: 1. **Amifostine** - A cytoprotectant free-radical scavenger that acts as a radioprotector. It's designed to reduce toxicity associated with chemotherapy and radiation therapy without compromising therapeutic efficacy[2]. 2. **Carboplatin** - A platinum-based chemotherapeutic agent that works by forming DNA crosslinks, thereby inhibiting DNA synthesis and function. 3. **Paclitaxel** - A taxane that promotes microtubule assembly and stabilizes microtubules against depolymerization, which inhibits cell division. ### Clinical Applications The combination has been studied in several cancer types: - **Advanced Endometrial Cancer**: In a study of 47 patients, the regimen showed a 40% response rate with a median progression-free survival of 7 months and median overall survival of 14 months[1]. - **Non-Small Cell Lung Cancer**: Used in a regimen where patients received induction therapy followed by concurrent weekly administration with hyperfractionated radiation therapy[2]. - **Head and Neck Cancer**: Administered with paclitaxel (40mg/m²) and carboplatin (100mg/m²) given intravenously weekly for six weeks, with amifostine given as subcutaneous injections prior to daily radiotherapy[4]. ### Dosing Regimens Different dosing schedules have been used in clinical trials: - For endometrial cancer: Carboplatin (AUC = 6), paclitaxel (175 mg/m²), and amifostine (740 mg/m²) every 4 weeks for 6 cycles[1]. - For NSCLC: Induction with paclitaxel 225 mg/m² and carboplatin AUC 6 on days 1 and 22, followed by concurrent weekly paclitaxel (50 mg/m²) and carboplatin (AUC 2) with amifostine 500 mg IV four times per week during chemoradiotherapy[2]. - For SCCHN: Weekly paclitaxel (40mg/m²) and carboplatin (100mg/m²) for six weeks with amifostine given as two 250mg subcutaneous injections prior to daily radiotherapy[4]. ### Toxicity Profile The combination appears to be reasonably well-tolerated: - In endometrial cancer patients, while 79% developed Grade 3/4 neutropenia, there were no episodes of Grade 4 febrile neutropenia and only one episode of infection with grades 3-4 neutropenia[1]. - In NSCLC, the addition of amifostine did not appear to compromise survival outcomes[2]. The regimen represents an approach that attempts to maintain efficacy while potentially reducing treatment-related toxicities through the addition of the cytoprotectant amifostine.

Other names

Paclitaxel/Carboplatin/Amifostine regimen3D-CHRT combination therapy